Patents by Inventor Tina Lavranos

Tina Lavranos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating acute myeloid leukemia
    Patent number: 11478445
    Abstract: The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC105P.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 25, 2022
    Assignee: Bionomics Ltd.
    Inventor: Tina Lavranos
  • METHOD FOR TREATING ACUTE MYELOID LEUKEMIA
    Publication number: 20210177797
    Abstract: The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC105P.
    Type: Application
    Filed: October 17, 2018
    Publication date: June 17, 2021
    Inventor: Tina Lavranos
  • METHOD OF MONITORING RESPONSE TO A TREATMENT
    Publication number: 20210148894
    Abstract: The present invention relates to the field of pharmacogenomics. In particular, provided herein is the use of pharmacodynamics markers in a method of monitoring the response of a subject to cancer treatment, wherein the cancer treatment comprises a Wnt/?-catenin signalling modulator (preferably an allosteric modulator of LGR5 receptor) and the monitoring comprises determining the ratio of Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) expression levels in a sample obtained from the subject.
    Type: Application
    Filed: April 12, 2019
    Publication date: May 20, 2021
    Inventors: Tina LAVRANOS, Kristen GEORGIOU
  • PHARMACEUTICAL COMBINATION AND USES THEREOF
    Publication number: 20210069147
    Abstract: The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 11, 2021
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Tina LAVRANOS, Daniel INGLIS
  • Combination Therapy for Treating Proliferative Diseases
    Publication number: 20200069729
    Abstract: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
    Type: Application
    Filed: November 9, 2019
    Publication date: March 5, 2020
    Inventors: Gabriel Kremmidiotis, Annabell Leske, Tina Lavranos
  • Combination Therapy for Treating Proliferative Diseases
    Publication number: 20180289739
    Abstract: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
    Type: Application
    Filed: February 20, 2018
    Publication date: October 11, 2018
    Inventors: Gabriel Kremmidiotis, Annabell Leske, Tina Lavranos
  • PHARMACEUTICAL COMBINATION AND USES THEREOF
    Publication number: 20180161302
    Abstract: The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 14, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Tina LAVRANOS, Daniel INGLIS
  • Combination Therapy for Treating Proliferative Diseases
    Publication number: 20140248375
    Abstract: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 4, 2014
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel Kremmidiotis, Annabell Leske, Tina Lavranos
  • Combination Therapy for Treating Proliferative Diseases
    Publication number: 20110130367
    Abstract: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
    Type: Application
    Filed: November 24, 2010
    Publication date: June 2, 2011
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel Kremmidiotis, Annabell Leske, Tina Lavranos